These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37797288)

  • 1. Does Slow and Steady Win the Race? Rates of Antipsychotic Discontinuation, Antipsychotic Dose, and Risk of Psychotic Relapse.
    McCutcheon RA; Taylor D; Rubio J; Nour J; Pillinger T; Murray RM; Jauhar S
    Schizophr Bull; 2024 Apr; 50(3):513-520. PubMed ID: 37797288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data.
    Schoretsanitis G; Kane JM; Correll CU; Rubio JM
    Schizophr Bull; 2022 Mar; 48(2):296-306. PubMed ID: 34355232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting psychotic relapse following randomised discontinuation of paliperidone in individuals with schizophrenia or schizoaffective disorder: an individual participant data analysis.
    Brandt L; Ritter K; Schneider-Thoma J; Siafis S; Montag C; Ayrilmaz H; Bermpohl F; Hasan A; Heinz A; Leucht S; Gutwinski S; Stuke H
    Lancet Psychiatry; 2023 Mar; 10(3):184-196. PubMed ID: 36804071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using in silico methods to determine optimal tapering regimens for decanoate-based long-acting injectable psychosis drugs.
    O'Neill JR; Taylor DM; Horowitz MA
    Ther Adv Psychopharmacol; 2024; 14():20451253241272790. PubMed ID: 39282238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia. A Meta-Analysis of Randomized Controlled Trials.
    Bogers JPAM; Hambarian G; Walburgh Schmidt N; Vermeulen JM; de Haan L
    Schizophr Bull; 2023 Jan; 49(1):11-23. PubMed ID: 36200866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial.
    Begemann MJH; Thompson IA; Veling W; Gangadin SS; Geraets CNW; van 't Hag E; Müller-Kuperus SJ; Oomen PP; Voppel AE; van der Gaag M; Kikkert MJ; Van Os J; Smit HFE; Knegtering RH; Wiersma S; Stouten LH; Gijsman HJ; Wunderink L; Staring ABP; Veerman SRT; Mahabir AGS; Kurkamp J; Pijnenborg GHM; Veen ND; Marcelis M; Grootens KP; Faber G; van Beveren NJ; Been A; van den Brink T; Bak M; van Amelsvoort TAMJ; Ruissen A; Blanke C; Groen K; de Haan L; Sommer IEC
    Trials; 2020 Feb; 21(1):147. PubMed ID: 32033579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials.
    Højlund M; Kemp AF; Haddad PM; Neill JC; Correll CU
    Lancet Psychiatry; 2021 Jun; 8(6):471-486. PubMed ID: 34023019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis.
    Kishi T; Ikuta T; Matsui Y; Inada K; Matsuda Y; Mishima K; Iwata N
    Psychol Med; 2019 Apr; 49(5):772-779. PubMed ID: 29909790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
    Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
    J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
    Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
    J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis.
    Bowtell M; Eaton S; Thien K; Bardell-Williams M; Downey L; Ratheesh A; Killackey E; McGorry P; O'Donoghue B
    Schizophr Res; 2018 May; 195():231-236. PubMed ID: 29066258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST).
    Winter-van Rossum I; Weiser M; Galderisi S; Leucht S; Bitter I; Glenthøj B; Hasan A; Luykx J; Kupchik M; Psota G; Rocca P; Stefanis N; Teitelbaum A; Bar Haim M; Leucht C; Kemmler G; Schurr T; ; Davidson M; Kahn RS; Fleischhacker WW
    Lancet Psychiatry; 2023 Mar; 10(3):197-208. PubMed ID: 36716759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone.
    Weiden PJ; Kim E; Bermak J; Turkoz I; Gopal S; Berwaerts J
    J Clin Psychiatry; 2017 Jul; 78(7):e813-e820. PubMed ID: 28640988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
    Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H
    JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis.
    Rubio JM; Schoretsanitis G; John M; Tiihonen J; Taipale H; Guinart D; Malhotra AK; Correll CU; Kane JM
    Lancet Psychiatry; 2020 Sep; 7(9):749-761. PubMed ID: 32828165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction).
    Moncrieff J; Lewis G; Freemantle N; Johnson S; Barnes TRE; Morant N; Pinfold V; Hunter R; Kent LJ; Smith R; Darton K; Horne R; Crellin NE; Cooper RE; Marston L; Priebe S
    BMJ Open; 2019 Nov; 9(11):e030912. PubMed ID: 31780589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia.
    Van Leeuwen E; Petrovic M; van Driel ML; De Sutter AI; Vander Stichele R; Declercq T; Christiaens T
    Cochrane Database Syst Rev; 2018 Apr; 3(3):CD007726. PubMed ID: 29605970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.